Hoe CRISPR de genêskunde flugger omskriuwt as regeljouwers byhâlde kinne
December 29, 2025 · Frisian News
Gene-editing technology CRISPR now treats blood disorders and cancers in clinics worldwide, but governments and health agencies struggle to keep pace with its speed and cost decisions.
FryskFerline moanne goedkeurde in klinyk yn Londen in CRISPR-behanneling foar in pasjint mei sikkelselanemie. De therapie koste 150.000 pûn en naam seis moannen yn beslag om te produsearjen. Twa jier lyn koe gjin inkeld sikehûs dit oanbiede bûten eksperimentele ûndersiken. Hjoed fiere klinieken yn de Feriene Steaten, Europa en Aazje CRISPR-programma's út. De technology wurket no. Regeljouwers hawwe noch net ôfpraat hoe't se dy priisje moatte, wa't betellet, of wat der bart as it net slagget.
De fluggens fan CRISPR syn klinysk gebrûk hat elk regelingssysteem dat it kontrôlearje moat ynhelle. It Europeesk Geneesmiddelen Buro keurret nije medisinen goed fia in proses dat jierren duorret. CRISPR-therapyen lykwols gean yn moannen fan lab nei pasjint, om't partikuliere klinieken yn lannen mei losse tafersjoch de behannellingen earst útfiere. Rike pasjinten fleane nei dizze klinieken, betelje kontant en keare nei hûs. Harren resultaten drukke dêrnei op regearingen om deselde behanneling yn eigen lân goed te keurjen. Regeljouwers folgje, se liede net.
Kosten meitsje in oar gat dat regeljouwers net folje kinne. Gentherapyen mei CRISPR koste tusken 100.000 en 500.000 dollar de pasjint, ôfhinklik fan de sykte. Sûnenssystemen yn rike lannen wrakselje om sels ien gefal it jier te finansierjen. Underwilens wize bioteknologybedriuwen op it persoanlike karakter fan elke therapie en stelle hege prizen foar echte kosten. Gjin lân hat de prizen noch omleech twongen, en gjin lân is oerienkomd wa't de kosten drage moat as in therapie net wurket. Dit lit gewoane minsken kieze tusken sparjen foar in hûs en har libben rêden.
It echte probleem rint djiper as snelheid of kosten. CRISPR wurket troch DNA te snijen en genetyske koade yn libbene sellen om te skriuwen. Off-target sneden kinne mutaasjes en kanker jierren letter feroarsaakje. Gegevens oer feilichheid op lange termyn binne der net, om't de technology te nij is. Regeljouwers yn de measte lannen fereaskje fiif oant tsien jier ferfolchgegevens foardat sy in genêsmiddel goedkeurje. CRISPR-therapyen hawwe op syn bêst twa jier gegevens. Pasjinten ûndertekenje tastimmingsformulieren dy't ûnbekende risiko's erkenne, mar regearingen hawwe net bepaald oft dizze tastimming allinnich bredere tapassing rjochtfeardiget.
Lytse lannen steane foar in kar: CRISPR ferbiede en sjen hoe't boargers yn it bûtenlân behanneling sykje, of it tastean en ferantwurdlikheid nimme foar ûnbekende skea. Grutte lannen stelle út, mei de hoop dat oare naasjes earst eksperimintearje. Underwilens gean ûndersikers en klinieken fierder. De technology wachtet net op amtners. Tsjin de tiid dat regeljouwers it iens binne oer regels, sil CRISPR nei oare sykten, oare seltypen, oare kompleksiteiten ferpleatst wêze dy't nimmen noch foarsizze kin.
A clinic in London last month approved CRISPR treatment for a patient with sickle cell disease. The therapy cost 150,000 pounds and took six months to manufacture. Two years ago, no hospital outside experimental trials could offer this at all. Today, clinics in the United States, Europe, and Asia run CRISPR programs. The technology now works. Regulators have not yet agreed on how to price it, who pays, or what happens when it fails.
The speed of CRISPR's clinical use has outpaced every regulatory system designed to control it. The European Medicines Agency approves new drugs through a process that takes years. CRISPR therapies, by contrast, move from lab to patient in months because private clinics in countries with loose oversight run the treatments first. Rich patients fly to these clinics, pay cash, and return home. Their results then pressure governments to approve the same treatment domestically. Regulators follow, not lead.
Cost creates another gap that regulators cannot fill. Gene therapies using CRISPR run between 100,000 and 500,000 dollars per patient depending on the disease. Health systems in wealthy countries struggle to fund even one case per year. Meanwhile, biotech firms point to the personalized nature of each therapy and claim high prices reflect real costs. No country has yet forced prices down, and no country has agreed on who should bear the cost when a therapy fails to work. This leaves ordinary people choosing between saving for a house and saving their life.
The real problem runs deeper than speed or cost. CRISPR works by cutting DNA and rewriting genetic code inside living cells. Off-target cuts can cause mutations and cancer years later. Long-term safety data does not exist because the technology is too new. Regulators in most countries require five to ten years of follow-up data before approving any drug. CRISPR therapies have perhaps two years of data at best. Patients sign consent forms acknowledging unknown risks, but governments have not decided whether this consent alone justifies wider use.
Small countries face a choice: ban CRISPR and watch citizens seek treatment abroad, or permit it and take responsibility for unknown harms. Large countries delay, hoping other nations run the experiments first. Meanwhile, researchers and clinics move forward. The technology will not wait for bureaucrats to catch up. By the time regulators agree on rules, CRISPR will have moved on to other diseases, other cell types, other complexities that nobody can yet predict.
Published December 29, 2025 · Frisian News · Ljouwert, Fryslân